AEGON ASSET MANAGEMENT UK Plc Sells 9,765 Shares of Insulet Corporation $PODD

AEGON ASSET MANAGEMENT UK Plc lessened its position in shares of Insulet Corporation (NASDAQ:PODD) by 9.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 92,041 shares of the medical instruments supplier’s stock after selling 9,765 shares during the period. AEGON ASSET MANAGEMENT UK Plc owned approximately 0.13% of Insulet worth $28,910,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Inspire Investing LLC lifted its holdings in shares of Insulet by 299.5% during the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock worth $1,082,000 after acquiring an additional 3,088 shares during the period. Gradient Investments LLC bought a new stake in shares of Insulet during the 2nd quarter worth approximately $17,429,000. Goldman Sachs Group Inc. lifted its holdings in shares of Insulet by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock worth $152,130,000 after acquiring an additional 10,628 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Insulet by 55.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier’s stock worth $1,376,000 after acquiring an additional 1,867 shares during the period. Finally, Vident Advisory LLC bought a new stake in shares of Insulet during the 1st quarter worth approximately $216,000.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Wells Fargo & Company upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. JPMorgan Chase & Co. upped their price objective on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Oppenheimer upped their price target on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Finally, Leerink Partners upped their price target on shares of Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a research report on Tuesday. Eighteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $348.05.

Insider Buying and Selling at Insulet

In other news, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Insulet Trading Up 1.2%

PODD opened at $318.30 on Wednesday. Insulet Corporation has a twelve month low of $226.50 and a twelve month high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company has a fifty day moving average of $325.03 and a 200-day moving average of $301.15. The stock has a market cap of $22.41 billion, a PE ratio of 96.75, a price-to-earnings-growth ratio of 2.63 and a beta of 1.40.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same period in the prior year, the company posted $0.55 earnings per share. Insulet’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.